{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT02065791_CREDENCE\\NCT02065791_CREDENCE_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Randomized subjects",
        "text": "Subjects who are randomized via the Interactive Web Response System (IWRS). For efficacy analyses and baseline summaries, subjects will be analyzed according to their randomization assignment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "ITT",
        "populationDescription": "Subjects who are randomized via the Interactive Web Response System (IWRS). For efficacy analyses and baseline summaries, subjects will be analyzed according to their randomization assignment.",
        "criteria": "Randomized via IWRS"
      },
      {
        "id": "pop_2",
        "name": "Treated subjects",
        "text": "Randomized subjects who receive at least one dose of double-blind study medication. For safety analysis (eg, adverse events [AEs]) and summary of exposure, subjects will be analyzed according to the predominant treatment received (defined as the treatment to which the subject was exposed for the greatest duration).",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "On-Study / On-Treatment",
        "populationDescription": "Randomized subjects who receive at least one dose of double-blind study medication. For safety analysis (eg, adverse events [AEs]) and summary of exposure, subjects will be analyzed according to the predominant treatment received (defined as the treatment to which the subject was exposed for the greatest duration).",
        "criteria": "Randomized AND received >=1 dose of double-blind study medication"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "eGFR",
        "code": "EGFR",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "eGFR",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Estimated glomerular filtration rate used for stratification (>=30 to <45, >=45 to <60, >=60 to <90 mL/min/1.73m2)"
      },
      {
        "id": "char_2",
        "name": "UACR",
        "code": "UACR",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "UACR",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Urinary albumin-to-creatinine ratio (level >300 mg/g to <=5,000 mg/g for eligibility)"
      },
      {
        "id": "char_3",
        "name": "Serum Creatinine",
        "code": "SERUM_CREATININE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Serum Creatinine",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline average derived from the Day 1 value and the value immediately preceding the Day 1 determination"
      }
    ],
    "summary": {
      "populationCount": 2,
      "characteristicCount": 3
    }
  }
}